Short Interest in Mainz Biomed (NASDAQ:MYNZ) Increases By 61.2%

Mainz Biomed (NASDAQ:MYNZ) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 128,500 shares, a growth of 61.2% from the February 28th total of 79,700 shares. Currently, 6.1% of the company’s stock are short sold. Based on an average daily trading volume, of 214,900 shares, the short-interest ratio is currently 0.6 days.

Mainz Biomed Stock Performance

Shares of NASDAQ MYNZ traded down $0.39 during mid-day trading on Friday, reaching $3.58. The company had a trading volume of 263,338 shares, compared to its average volume of 96,360. The stock has a market capitalization of $7.16 million, a PE ratio of -0.05 and a beta of 0.33. Mainz Biomed has a twelve month low of $3.29 and a twelve month high of $45.20. The stock’s 50 day moving average is $5.40 and its 200-day moving average is $7.40.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new position in Mainz Biomed (NASDAQ:MYNZ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, Maxim Group assumed coverage on Mainz Biomed in a research note on Friday, February 14th. They set a “buy” rating and a $14.00 target price on the stock.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.